@article{d308a3d30b7e45f99d7ac990d8edf014,
title = "Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma",
abstract = "To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma.",
author = "Schey, {S A} and P Fields and Bartlett, {J B} and Clarke, {I A} and G Ashan and Knight, {R D} and M Streetly and Dalgleish, {A G}",
year = "2004",
doi = "10.1200/JCO.2004.10.052",
language = "English",
volume = "22",
pages = "3269--76",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",
}